5.4 Collateral Information and Testing Interpretation

Using Collateral Information

Collateral information is relevant data from sources other than the client: prior treatment records, referral documents, family reports, probation information, medical records, prescription-monitoring data when properly available, and observations from the care team. It is valuable because substance-use assessment often involves incomplete memory, shame, fear, intoxication, cognitive impairment, or external pressure. Collateral data can confirm dates, consequences, prior diagnoses, medications, overdose events, withdrawal history, and safety concerns. It can also be wrong, biased, outdated, or legally unavailable.

Consent and confidentiality govern all of this. SUD records are protected by 42 CFR Part 2, which is generally stricter than HIPAA: before contacting a family member or outside provider, the counselor follows agency policy and applicable law, obtains appropriate written authorization when required, and limits the request to relevant information. In genuine emergencies, law and policy may permit limited disclosures, but the exam usually expects the least intrusive clinically appropriate action.

Interpreting Drug and Alcohol Testing

Toxicology is another data point, not a verdict. Methods differ in purpose and timing: breath testing estimates current alcohol level; urine is the most common drug panel; blood is precise but invasive; saliva detects recent use; and hair can reflect a roughly 90-day window. At ADC exam level, do not overclaim exact detection windows unless the stem provides them. Focus on what a result can and cannot say.

A positive test indicates recent exposure but does not establish impairment, diagnosis, intent, amount used, or level of care. A negative test does not prove the absence of a substance use disorder, because the substance may fall outside the detection window, be excluded from the panel, be diluted, or simply not be used recently. Initial immunoassay screens can produce false positives, so confirmatory testing (such as GC-MS) may be needed when results carry consequences.

Common detection-window generalizations help interpret results, though the exam will give specifics if it wants them: most drugs are detectable in urine for roughly one to three days, while chronic cannabis use can be detected for weeks; alcohol leaves the breath and blood within hours but biomarkers such as EtG can extend the window. Beyond timing, the counselor watches for specimen-validity issues: a dilute, adulterated, or substituted sample is itself clinically meaningful and is documented as observed, not interpreted as proof of guilt.

Specimen-validity testing checks creatinine, specific gravity, pH, and oxidant/adulterant markers to flag tampering; a result reported as dilute or invalid is not the same as negative and usually prompts a recollection.

Two-step testing is the professional standard: a presumptive immunoassay screen, then a definitive confirmatory method such as GC-MS or LC-MS/MS for any result with consequences, because immunoassays cross-react (poppy seeds, some decongestants, certain antidepressants) and can read falsely positive. The counselor reports test data as one corroborating source and pairs surprising results with a respectful, safety-focused conversation. "

Integrating Sources Without Shaming

Applied CADC guidance: a client denies opioid use, but the referral packet reports two recent overdoses and a urine screen is positive. The counselor should not shame the client or end the interview. The better response reviews confidentiality and purpose, asks open questions about safety and recent use, assesses overdose risk (including naloxone education), considers medical referral, and documents the discrepancy objectively.

Document facts separately from impressions. Write, "Client denies use since Friday; referral reports overdose Saturday and urine positive for fentanyl metabolite per lab report," not "Client is lying." This protects the client, the counselor, and the treatment team, and it preserves a defensible record.

Discrepancies are clinical information, not character verdicts. A gap between self-report and a test or collateral source can reflect fear of consequences, shame, memory gaps from intoxication, a different definition of "use," or a genuinely inaccurate outside source. The skilled response is curiosity: the counselor names the discrepancy gently, asks the client to help make sense of it, and re-checks safety. This stance preserves engagement and often yields more accurate information than confrontation, which tends to harden denial.

When the discrepancy involves an immediate danger, however, the counselor acts on the safety concern first and reconciles the narrative afterward.

Common Exam Traps

• Treating collateral information as automatically more truthful than the client. A spouse may exaggerate, a client may minimize, and a test may be misread. The counselor integrates sources, seeks clarification, and records each source's content distinctly.
• Requesting or sharing information without a release. In a nonemergency, obtain or verify an appropriate authorization and follow 42 CFR Part 2 before disclosing or even confirming that the client is in treatment.
• Ignoring safety because the client disputes the data. If collateral information suggests overdose, withdrawal seizures, suicidal threats, child-safety concerns, or medical instability, the counselor must assess immediate risk and follow mandated procedures regardless of the client's objection.

On IC&RC-style items, the best answer usually balances accuracy and ethics: use collateral information to improve assessment, not to punish; use testing to inform follow-up, not to replace the interview.